NASDAQ
29.07.25 | 21:58
9,630 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | Arcus Biosciences' cancer drug gets orphan drug status | 1 | Seeking Alpha | ||
| 10.07. | Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For Pancreatic Cancer | - | RTTNews | ||
| 08.07. | Arcus Biosciences February 2025 slides: oncology pipeline progresses despite Q1 miss | 3 | Investing.com | ||
| 01.07. | Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment | 1 | Insider Monkey | ||
| 12.06. | Arcus Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.06. | H.C. Wainwright bekräftigt Kaufempfehlung für Arcus Biosciences-Aktie | 1 | Investing.com Deutsch | ||
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 02.06. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.04. | Forecasting The Future: 5 Analyst Projections For Arcus Biosciences | 2 | Benzinga.com | ||
| 26.02. | Arcus Biosciences stock rating upgraded to Buy at H.C. Wainwright | 23 | Investing.com | ||
| 25.02. | Arcus Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 25.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.02. | Arcus Biosciences stock target cut to $18 at H.C. Wainwright | 4 | Investing.com | ||
| 18.02. | Arcus Biosciences Shares Are Down Today: What's Going On? | 1 | Benzinga.com | ||
| 18.02. | Arcus Biosciences Prices 13.6 Mln Offering At $11.00/shr, Stock Slide In Pre-market | 1 | RTTNews | ||
| 18.02. | Arcus Biosciences stock dips after pricing $150M offering | 1 | Seeking Alpha | ||
| 18.02. | Arcus Biosciences advances cancer drug casdatifan post Gilead deal expiry | 5 | Investing.com | ||
| 18.02. | Arcus Biosciences treibt Krebsmedikament Casdatifan nach Auslaufen des Gilead-Deals voran | 16 | Investing.com Deutsch | ||
| 18.02. | Arcus Biosciences sets $11/share for $150M stock offering | 1 | Investing.com |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 0,740 | -2,18 % | InflaRx N.V.: InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement | JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,995 | +1,48 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| XOMA ROYALTY | 22,200 | -3,48 % | ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction | SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,762 | +6,15 % | Rocket Pharmaceuticals cuts headcount, realigns pipeline | ||
| VANDA PHARMACEUTICALS | 4,100 | +0,99 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S | WASHINGTON, June 10, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the first dose in the first-in-human clinical trial... ► Artikel lesen | |
| ROIVANT SCIENCES | 9,884 | 0,00 % | Roivant Sciences: Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 | ||
| CARTESIAN THERAPEUTICS | 11,100 | -0,89 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen | |
| ANNOVIS BIO | 2,365 | +2,83 % | Annovis Bio Inc.: Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance | MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| ADVERUM BIOTECHNOLOGIES | 2,100 | -7,08 % | Adverum Biotechnologies, Inc.: Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement... ► Artikel lesen | |
| QUINCE THERAPEUTICS | 1,680 | 0,00 % | Quince, A Bright Spot In Struggling D2C Fashion Space, More Than Doubles Valuation To $4.5B With Second Raise In 6 Months | ||
| VERA THERAPEUTICS | 20,720 | -0,72 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| INMUNE BIO | 2,620 | -3,68 % | INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge? | ||
| SEPTERNA | 12,810 | 0,00 % | Septerna, Inc.: Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results | Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 40,140 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| EVOTEC | 7,658 | +3,49 % | ÜBERNAHMEFANTASIE! Barrick Mining, Evotec, Desert Gold Aktie | Wie die hohen Preise hält sich auch die Übernahmefantasie im Goldsektor. Als Kandidat wird immer wieder Desert Gold genannt. Mit der spannenden Akquisition in Westafrika hat der Explorer diversifiziert... ► Artikel lesen |
Das Unternehmen ARCUS BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 9,630 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.